It was back in 2005 when we first reported on studies which demonstrated an increased risk of “poor neonatal adaptation” in infants with prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants in late pregnancy. Since that time, reports consistently indicate that about 25%-30% of infants exposed to SSRIs late in pregnancy manifest symptoms of […]
Tag Archives | SSRIs
Two thirds of all breast cancer tumors are known to have receptors that respond to hormones; that is they can grow in response to estrogen. Tamoxifen is a medication which selectively blocks estrogen receptors on breast cancer tumors and, in this fashion, reduces the risk of recurrence by half in women with estrogen receptor-positive breast […]
The following post was first published in OB/GYN News.
We have received many emails and calls from colleagues and patients regarding the recent article on the safety of SSRI use during pregnancy published in the New York Times. In this article, health writer Roni Caryn Rabin, detailed the risks associated with the use of antidepressants during pregnancy.
Last year, the FDA approved the first non-hormonal treatment for hot flashes – a 7.5-mg formulation of the selective serotonin reuptake inhibitor (SSRI) paroxetine which was marketed under the name of Brisdelle. A new study suggests that low dose paroxetine (7.5 mg) not only helps with vasomotor symptoms, it can also improve sleep. In a […]
Many women are understandably concerned about the risk of weight gain associated with antidepressants. It is difficult to advise them as to which antidepressants are less or more likely to cause weight gain, as there are no head-to-head comparisons. In a recent electronic health record study including data from 22,610 individuals, 19,244 of which were […]
Various selective serotonin reuptake inhibitors (SSRIs), including citalopram (Celexa), escitalopram (Lexapro) and paroxetine (Paxil), have been shown to be effective for the treatment of menopausal vasomotor symptoms (VMS). Other studies have supported the efficacy of the serotonin–norepinephrine reuptake inhibitors (SNRIs) duloxetine (Cymbalta) and venlafaxine (Effexor). The FDA recently approved a 7.5-mg formulation of paroxetine (marketed as Brisdelle) as the first non-hormonal treatment of hot flashes.
Two recent epidemiologic studies have demonstrated an association between prenatal exposure to selective serotonin reuptake inhibitor antidepressants (SSRIs) with autism spectrum disorders (ASD; Croen et al 2011, Rai et al, 2013). One important imitation of these two studies is that parental psychiatric disorder in itself is associated with an increased risk of ASD in the offspring, and these studies could not distinguish between the effects of drug exposure and the consequences of the underlying maternal psychiatric illness. Two new studies shed light on the association between prenatal antidepressant exposure and risk of autism spectrum disorder in the offspring.
The FDA recently approved a 7.5-mg formulation of the selective serotonin reuptake inhibitor (SSRI) paroxetine mesylate for the treatment of hot flashes. It will be marketed under the name of Brisdelle.
It is estimated that autism spectrum disorders (ASD) affect about 1% to 2% of children. Research carried out in twins and families indicate that ASD is highly heritable; however, it is generally believed that while genetic factors play an important role, there is an interplay between genetic and environmental factors in the etiology of this disorder. Various environmental exposures have been implicated, including vaccinations, mercury, air pollution, insecticides, and infection.